HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gold(I) complexes of 9-deazahypoxanthine as selective antitumor and anti-inflammatory agents.

Abstract
The gold(I) mixed-ligand complexes involving O-substituted derivatives of 9-deazahypoxanthine (HLn) and triphenylphosphine (PPh3) with the general formula [Au(Ln)(PPh3)] (1-5) were prepared and thoroughly characterized by elemental analysis, FT-IR and multinuclear NMR spectroscopy, ESI+ mass spectrometry, single crystal X-ray (HL5 and complex 2) and TG/DTA analyses. Complexes 1-5 were evaluated for their in vitro antitumor activity against nine human cancer lines, i.e. MCF7 (breast carcinoma), HOS (osteosarcoma), A549 (adenocarcinoma), G361 (melanoma), HeLa (cervical cancer), A2780 (ovarian carcinoma), A2780R (ovarian carcinoma resistant to cisplatin), 22Rv1 (prostate cancer) and THP-1 (monocytic leukaemia), for their in vitro anti-inflammatory activity using a model of LPS-activated macrophages, and for their in vivo antiedematous activity by λ-carrageenan-induced hind paw edema model on rats. The results showed that the complexes 1-5 exhibit selective in vitro cytotoxicity against MCF7, HOS, 22Rv1, A2780 and A2780R, with submicromolar IC50 values for 2 against the MCF7 (0.6 µM) and HOS (0.9 µM). The results of in vitro cytotoxicity screening on primary culture of human hepatocytes (HEP220) revealed up to 30-times lower toxicity of compounds against healthy cells as compared with cancer cells. Additionally, the complexes 1-5 significantly influence the secretion and expression of pro-inflammatory cytokines TNF-α and IL-1β by a similar manner as a commercially used anti-arthritic drug Auranofin. The tested complexes also significantly influence the rate and overall volume of the edema, caused by the intraplantar application of λ-carrageenan polysaccharide to rats. Based on these promising results, the presented compounds could qualify to become feasible candidates for advanced testing as potential antitumor and anti-inflammatory drug-like compounds.
AuthorsJán Vančo, Jana Gáliková, Jan Hošek, Zdeněk Dvořák, Lenka Paráková, Zdeněk Trávníček
JournalPloS one (PLoS One) Vol. 9 Issue 10 Pg. e109901 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID25333949 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 9-deazahypoxanthine
  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Hypoxanthines
  • Gold
Topics
  • Animals
  • Anti-Inflammatory Agents (chemistry, pharmacology, therapeutic use)
  • Antineoplastic Agents (chemistry, pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Disease Models, Animal
  • Edema (drug therapy)
  • Gold (chemistry, pharmacology, therapeutic use)
  • Hepatocytes (drug effects)
  • Humans
  • Hypoxanthines (chemistry, pharmacology, therapeutic use)
  • Inflammation (drug therapy)
  • Neoplasms (drug therapy)
  • Rats
  • Spectroscopy, Fourier Transform Infrared

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: